Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Investment analysts at Wedbush increased their Q3 2017 earnings estimates for Voyager Therapeutics in a report issued on Tuesday. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.76) per share for the quarter, up from their prior estimate of ($0.78). Wedbush currently has a “Positive” rating and a $31.00 price target on the stock. Wedbush also issued estimates for Voyager Therapeutics’ Q4 2017 earnings at ($0.82) EPS, FY2017 earnings at ($2.95) EPS, Q1 2018 earnings at ($0.76) EPS, Q2 2018 earnings at ($0.77) EPS, Q3 2018 earnings at ($0.65) EPS, Q4 2018 earnings at ($0.67) EPS, FY2018 earnings at ($2.84) EPS, FY2019 earnings at ($2.86) EPS, FY2020 earnings at ($3.20) EPS and FY2021 earnings at ($2.29) EPS.

Several other equities analysts have also commented on the company. Stifel Nicolaus reissued a “buy” rating and set a $31.00 price target (up from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Zacks Investment Research lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Canaccord Genuity started coverage on Voyager Therapeutics in a research report on Friday, October 27th. They set a “buy” rating and a $35.00 price target on the stock. ValuEngine raised Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Raymond James Financial, Inc. started coverage on Voyager Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $35.00 price target on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. Voyager Therapeutics has an average rating of “Buy” and a consensus target price of $28.89.

COPYRIGHT VIOLATION NOTICE: “Q3 2017 Earnings Estimate for Voyager Therapeutics, Inc. (VYGR) Issued By Wedbush” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/q3-2017-earnings-estimate-for-voyager-therapeutics-inc-vygr-issued-by-wedbush.html.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). The firm had revenue of $1.18 million during the quarter, compared to analyst estimates of $3.27 million. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. raised its position in shares of Voyager Therapeutics by 0.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock valued at $261,000 after purchasing an additional 114 shares in the last quarter. Fiduciary Trust Co. raised its position in shares of Voyager Therapeutics by 0.4% in the 2nd quarter. Fiduciary Trust Co. now owns 109,034 shares of the company’s stock valued at $977,000 after purchasing an additional 473 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Voyager Therapeutics by 8.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after purchasing an additional 1,399 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Voyager Therapeutics by 8.4% in the 2nd quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after purchasing an additional 2,000 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its position in shares of Voyager Therapeutics by 11.8% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 37,295 shares of the company’s stock valued at $334,000 after purchasing an additional 3,939 shares in the last quarter. 40.72% of the stock is currently owned by institutional investors.

In other Voyager Therapeutics news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $10.00, for a total value of $54,900.00. Following the transaction, the insider now directly owns 17,157 shares of the company’s stock, valued at approximately $171,570. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders sold 32,940 shares of company stock worth $490,092. 8.00% of the stock is currently owned by corporate insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.